Pegfilgrastim Subcutaneous

Uncategorized

Pegfilgrastim Subcutaneous

What is Pegfilgrastim Subcutaneous
?

Pegfilgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF) indicated for the reduction of the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

Pegfilgrastim is a biosimilar to Neulasta® (filgrastim), and is produced by recombinant DNA technology in Chinese hamster ovary cells. Pegfilgrastim is a single-chain, glycosylated, polypeptide containing 174 amino acids and has a molecular weight of 19,569 daltons. Pegfilgrastim is biologically equivalent to Neulasta® (filgrastim) in terms of structure, function, and biosynthesis.

Pegfilgrastim is a G-CSF that is used to stimulate the production of white blood cells in people receiving

Benefits of Pegfilgrastim Subcutaneous
and Its Uses.

Pegfilgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) analogue used to accelerate white blood cell production in patients with cancer who are receiving chemotherapy. Pegfilgrastim is available as a subcutaneous injection.

Pegfilgrastim is indicated to reduce the incidence of neutropenia and its associated complications, such as fever, infection, and sepsis, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

Pegfilgrastim is also approved to increase survival in patients with acute myeloid leukemia (AML) following induction chemotherapy.

Pegfilgrastim is a long-acting G-CSF analogue with a half-life of approximately four days. It binds to specific receptors on the surface of neutrophils, stimulating proliferation and differentiation. This leads to increased numbers of neutrophils, which can combat infection

Side Effects and Dosage of Pegfilgrastim Subcutaneous

Pegfilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. Pegfilgrastim is used to stimulate white blood cell production in patients receiving cancer chemotherapy. The most common side effects of pegfilgrastim are bone pain and redness, warmth, swelling, or itching at the site of injection. Rare but serious side effects include severe allergic reaction and heart problems.

Pegfilgrastim is available as a subcutaneous injection. The usual dosage is 6 mg given once per chemotherapy cycle.

Category: Uncategorized
Posts created 12429

Leave a Reply

Your email address will not be published.

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top